Navigation Links
According to Surveyed EU5 Oncologists, Zelboraf Captures 50 Percent Patient Share of the First-Line BRAF-Mutation Positive Malignant Melanoma Population

EXTON, Pa., Dec. 2, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, according to oncologists surveyed in Q3 2013, Roche/Genentech/Daiichi Sankyo/Chugai's Zelboraf, on average, garners 50 percent patient share across the EU5, in the first-line BRAF-mutation positive setting. In the BRAF-wild-type (BRAF-negative) population, treatment is still dominated by the alkylating agent, dacarbazine (generics). Surveyed oncologists also report that Bristol-Myers Squibb's Yervoy holds, on average, nearly one-third of patient share in second-line BRAF-mutation-positive setting, according to surveyed EU5 oncologists; however, penetration of Yervoy across the EU5 is variable. The vast majority of surveyed respondents cite moderate to high satisfaction with Yervoy and Zelboraf, and surveyed oncologists anticipate a significant increase in first-line prescribing of these agents in BRAF-wild-type and BRAF-mutation-positive malignant melanoma, within the next six months.

(Logo: )

According to the data published in the TreatmentTrends® Malignant Melanoma (EU) Q4 2013 report, surveyed EU5 medical oncologists and dermatologists, with the exception of respondents from Spain, report that low-dose Intron A (Merck) garners more patient share than high-dose Intron A as adjuvant treatment for resectable malignant melanoma. High-dose Intron A has significant perceived advantage over low-dose Intron A with respect to efficacy attributes. Conversely, low-dose Intron A has a perceived advantage on safety and tolerability and outperforms high-dose Intron A on experience/familiarity, cost to healthcare system and ease of administration. 

"Physicians surveyed in 2013 report significantly higher rates of BRAF-mutation screening in their unresectable and metastatic patients compared with survey findings from 2012; however, we still see variation in BRAF-screening rates across the EU5," said Decision Resources Group Senior Business Insights Analyst Karen Pomeranz, M.Sc., Ph.D. "Surveyed oncologists expect BRAF-screening to increase in almost all stages of disease within the next six months, whereas surveyed dermatologists expect screening rates to significantly increase in only their earlier-stage resectable patients."

TreatmentTrends® Malignant Melanoma (EU) is a syndicated report designed to provide a view of the current and future management of malignant melanoma based on primary research fielded with 252 medical oncologists in Europe (France, Germany, Italy, Spain, United Kingdom) and 68 dermatologists (Germany only). The report evaluates treatment and diagnosis patterns of the disease and physician opinions on possible future therapy options. BioTrends Oncology is also covering the launch of Tafinlar and Mekinist through its LaunchTrends® studies.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group 
Christopher Comfort 

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. According to Surveyed U.S. Oncologists, Zelboraf is the Patient Share Leader in First-Line BRAF-Mutation Positive Malignant Melanoma
2. mHealth market is Expected to Reach $58.8 Billion Globally by 2020 According to Allied Market Research Projections
3. More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely Candidates for FG-4592/ASP1517, According to Surveyed EU5 Nephrologists
4. According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer
5. In Terms of Effect on Overall Survival, Current and Emerging Therapies Have No Advantage Over Avastin/FOLFIRI in the Treatment of Second-Line Metastatic Colorectal Cancer, According to Clinical Data and Thought Leader Opinion
6. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
7. Annual Healthcare Cost for a Typical American Family is $22,030 According to 2013 Milliman Medical Index
8. Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance
9. Fewer Venture Capital Dollars Invested Into Life Sciences Companies In Q1 2013, According To The MoneyTree Report
10. Food Recalls Driven by Companies Issuing Multiple Recalls in the First Quarter of 2013, According to Latest ExpertRECALL Index
11. Nearly 8 Million Healthcare Personnel Come in Contact with Chemotherapy Drugs, According to CDC
Post Your Comments:
(Date:11/24/2015)... 24, 2015  Enova Illumination is pleased to announce ... Helsinki, Finland to combine their world class ... cutting edge of medical visualization: Enova is the first ... United States and Novocam is the manufacturer ... the world,s most powerful battery-operated LED headlight with high-quality ...
(Date:11/24/2015)... 24, 2015  BioPlast Manufacturing, a manufacturer of ... clinical diagnostic and biotech environments, announced today that ... quality petri dishes. This acquisition is aligned with ... of products that are designed and tested by ... quality.  Bristol, Pennsylvania ...
(Date:11/24/2015)... 2015  Eyewear brand Revo has debuted a ... singer and activist Bono as part of the " Buy ... blindness in more than 5 million people by 2020.  ... $10 from the sale of every pair of Revo sunglasses, ... of $10 million to the "Buy Vision, Give Sight" initiative. ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... Brillouin Energy Corp. Congress and ... developer of renewable energy technologies capable of producing commercially useful amounts of thermal ... its WET™ and HHT™ Boiler System reactor core modules were presented to Congress ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Family Care (AFC), the ... of a holiday pop-up clinic located in Metro Atlanta’s North Point Mall. The clinic ... and different way. The location is scheduled to operate through Dec. 24. , Holiday ...
(Date:11/24/2015)... ... November 24, 2015 , ... Abington Hospital – ... Institute of Quality® Bariatric Surgery Facility for treating individuals living with morbid or ... care services available to its members to help them make informed decisions about ...
(Date:11/24/2015)... ... 2015 , ... Bibliomotion is thrilled to announce the launch of ... Diversity by Nancy M. Schlichting, Chief Executive Officer of Henry Ford Health ... the needs of patients and their families, shaped my desire to improve the system ...
(Date:11/24/2015)... Nashville, Tennessee (PRWEB) , ... November 24, 2015 , ... ... 2015-2016 Pharmacy Quality Trend Report . Throughout the past year there have been multiple ... more mature state. During this transition, PharmMD has enabled their customers and partners to ...
Breaking Medicine News(10 mins):